Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Targeted Oncology
Published in: Targeted Oncology 2/2017

01-04-2017 | Erratum

Erratum to: A combination of the telomerase inhibitor, BIBR1532, and paclitaxel synergistically inhibit cell proliferation in breast cancer cell lines

Authors: Yi Shi, Lin Sun, Ge Chen, Dongyan Zheng, Li Li, Wanguo Wei

Published in: Targeted Oncology | Issue 2/2017

Login to get access

Excerpt

Erratum to: Targ Oncol (2015) 10:565–573 …
Metadata
Title
Erratum to: A combination of the telomerase inhibitor, BIBR1532, and paclitaxel synergistically inhibit cell proliferation in breast cancer cell lines
Authors
Yi Shi
Lin Sun
Ge Chen
Dongyan Zheng
Li Li
Wanguo Wei
Publication date
01-04-2017
Publisher
Springer International Publishing
Published in
Targeted Oncology / Issue 2/2017
Print ISSN: 1776-2596
Electronic ISSN: 1776-260X
DOI
https://doi.org/10.1007/s11523-017-0475-8

Other articles of this Issue 2/2017

Targeted Oncology 2/2017 Go to the issue

Review Article

The Multifaceted Roles of B Cells in Solid Tumors: Emerging Treatment Opportunities

Adis Drug Evaluation

Sorafenib: A Review in Hepatocellular Carcinoma

Therapy in Practice

Anti-PD-L1 atezolizumab-Induced Autoimmune Diabetes: a Case Report and Review of the Literature

Review Article

miRNAs as Biomarkers and Therapeutic Targets in Non-Small Cell Lung Cancer: Current Perspectives

Adis Drug Evaluation

Obinutuzumab: A Review in Rituximab-Refractory or -Relapsed Follicular Lymphoma

Leading Article

Immuno-Oncology: The Third Paradigm in Early Drug Development
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits